Patent Assignment
Reel/Frame 012607/0038
Change of Name
Recorded: 2002-02-11
Received: 2002-02-27
Pages: 17
Assignor
DUPONT PHARMACEUTICALS COMPANY
Executed: 2001-10-01
Assignee
BRISTOL-MYERS SQUIBB PHARMA COMPANY
PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543, UNITED STATES
Covered Properties
(100)
Substituted amino methyl factor Xa inhibitors
Application:
60/337,051 →
Glycinamides S factor XA inhibitors
Application:
60/336,994 →
Novel N-[4-(1H-imidazol-1-YL)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as factor XA inhibitors
Application:
60/336,972 →
Synthesis of 1,3,5-Trisubstituted Pyrazoles
Application:
10/005,938 →
3- (2,4-Dimethylthiazol-5-Yl) Indeno [1,2-C]Pyrazol-4-One Derivatives and Their Uses
Application:
10/000,820 →
Simultaneous Imaging of Cardiac Perfusion and a Vitronectin Receptor Targeted Imaging Agent
Application:
09/995,388 →
Crf Receptor Antagonists and Methods Relating Thereto
Application:
09/995,159 →
Efavirenz tablet formulation having unique biopharmaceutical characteristics
Application:
60/333,651 →
Assays to assess conformational changes of integrins induced by ligand binding based on electrophoretic mobility
Application:
09/994,493 →
Pyrazolotriazines as Crf Antagonists
Application:
09/990,138 →
3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
Application:
60/331,829 →
Simultaneous Dual Isotope Imaging of Cardiac Perfusion and Cardiac Inflammation
Application:
10/002,359 →
Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
Application:
10/003,972 →
Beta-sulfone derivatives as inhibitors of matrix metalloproteases and TNF-alpha
Application:
60/335,962 →
Heterocyclic Piperidines as Modulators of Chemokine Receptor Activity
Application:
09/981,833 →
Bicyclic lactam derivatives as inhibitors of matrix metalloproteases and TNF-alpha
Application:
60/329,636 →
Assays and Peptide Substrate for Determining Aggrecan Degrading Metallo Protease Activity
Application:
09/975,813 →
Cyclic sulfone derivatives as inhibitors of matrix metalloproteases and TNF-alpha
Application:
60/327,816 →
Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof
Application:
09/969,256 →
Compounds useful for treating hepatitis C virus
Application:
60/324,874 →
Efficient Process for the Preparation of a Factor Xa Inhibitor
Application:
09/960,040 →
Amide and carbamate containing bis-amino acid sulfonamide inhibitors of HIV protease
Application:
60/323,042 →
Piperazin-one alkyl ureas as CCR3 receptor modulators
Application:
60/323,166 →
Cyclic Sulfonyl Compounds as Inhibitors of Metalloproteases
Application:
09/954,379 →
Cyclic B-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-a
Application:
60/322,630 →
Systems and methods for weighing and charging
Application:
60/318,285 →
Vitronectin Receptor Antagonist Pharmaceuticals
Application:
09/947,783 →
Vitronectin Receptor Antagonist Pharmaceuticals
Application:
09/948,807 →
Vitronectin Receptor Antagonist Pharmaceuticals
Application:
09/948,390 →
Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
Application:
60/317,529 →
Novel chemical library synthesis particles
Application:
60/315,575 →
Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
Application:
60/313,552 →
Tetrahydroquinoline derivatives as antithrombotic agents
Application:
60/313,549 →
Bicyclic hydroxamates as inhibitors of matrix metalloproteases and tumor necrosis factor-alpha
Application:
60/313,052 →
Azolo triazines and pyrimidines
Application:
09/930,782 →
Gas Microsphere Liposome Composites for Ultrasound Imaging and Ultrasound Stimulated Drug Release
Application:
09/931,317 →
Selective estrogen receptor modulators
Application:
60/311,466 →
Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
Application:
60/310,859 →
Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
Application:
60/310,761 →
Novel Guanidine Mimics as Factor Xa Inhibitors
Application:
09/924,381 →
Process for the Preparation of Macrocyclic Metalloprotease Inhibitors
Application:
09/919,564 →
4,4-Disubstituted-1, 4-Dihydro-2H-3, 1-Benzoxazin-2-Ones Useful as Hiv Reverse Transcriptase Inhibitors and Intermediates and Processes for Making the Same
Application:
09/919,065 →
Isoxazolo [4,5-d] pyrimidines as CRF antagonists
Application:
09/912,837 →
Efficient Ligand-Mediated Ullmann Coupling of Anilnies and Azoles
Application:
09/912,950 →
Asymmetric Synthesis of Quinazolin-2-Ones Useful as Hiv Reverse Transcriptase Inhibitors
Application:
09/909,731 →
Tricyclic-2-Pyridone Compounds Useful as Hiv Reverse Transcriptase Inhibitors
Application:
09/908,995 →
CRF2 ligands in combination therapy
Application:
09/908,825 →
Crystalline and salt forms of an HIV protease inhibitor
Application:
09/908,430 →
Salt forms of an HIV protease inhibitor
Application:
09/908,126 →
Phosphate Esters of Bis-Amino Acid Sulfonamides Containing Substituted Benzyl Amines
Application:
09/908,431 →
Acylsemicarbazides as Cyclin Dependent Kinase Inhibitors Useful as Anti-Cancer and Anti-Proliferative Agents
Application:
09/906,963 →
Novel Isoxazoline Fibrinogen Receptor Antagonists
Application:
09/905,321 →
Imidazo[1,2-A]Pyrazines for the Treatment of Neurological Disorders
Application:
09/905,097 →
Novel Isoxazoline Fibrinogen Receptor Antagonists
Application:
09/905,417 →
Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
Application:
60/305,067 →
Terahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
Application:
60/304,921 →
Novel 4-Phenyl Substituted Tetrahydroisoquinolines and Therapeutic Use Thereof
Application:
09/902,845 →
Novel Lactam Metalloprotease Inhibitors
Application:
09/901,937 →
6-Substituted pyrazolo[3,4-D]pyrimidin-4-ones useful as cyclin dependant kinase inhibitors
Application:
60/304,084 →
Semicarbazides and their uses
Application:
60/303,519 →
Stable radiopharmaceutical compositions and methods for preparation thereof
Application:
09/899,629 →
Pyrrolo [3,4-D] Pyrimidines as Corticotropin Releasing Factor (Crf) Antagonists
Application:
09/898,326 →
Imidazo-Heterobicycles as Factor Xa Inhibitors
Application:
09/898,279 →
Thrombin or Factor Xa Inhibitors
Application:
09/896,939 →
N-Ureidoheterocycloalkyl-Piperidines as Modulators of Chemokine Receptor Activity
Application:
09/895,138 →
Heteroaryl- Phenyl Heterobicyclic Factor Xa Inhibitors
Application:
09/887,850 →
Heteroaryl-Phenyl Substituted Factor Xa Inhibitors
Application:
09/887,936 →
Piperidine Amides as Modulators of Chemo Kine Receptor Activity
Application:
09/885,550 →
Hepatitis C protease exosite for inhibit or design
Application:
09/878,579 →
Lactams Substituted by Cyclic Succinates as Inhibitors of a Beta Protein Production
Application:
09/871,840 →
Hydantoins and related heterocycles as inhibitors of matrix metalloproteases and tumor necrosis factor-alpha
Application:
60/293,571 →
Bicyclic inhibitors of factor Xa
Application:
60/292,665 →
Use of Small Molecule Radioligands to Discover Inhibitors of Amyloid-Beta Peptide Production and for Diagnostic Imaging
Application:
09/859,261 →
Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
Application:
60/290,706 →
Tricyclic fused pyridine and pyrimidine derivatives as CRF antagonists
Application:
09/845,867 →
Tricyclic compounds useful as HIV reverse transcriptase inhibitors
Application:
60/284,818 →
Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors
Application:
60/284,856 →
1,4,5,6-Tetrahydropyrazolo-[3,4-C]-pyridin-7-ones as factor Xa inhibitors
Application:
60/284,615 →
1, 4, 5, 6-tetrahydropyrazolo-[3,4-C]-pyridin-7-ones as factor Xa inhibitors
Application:
60/284,614 →
Nitrogen Containing Heteroaromatics with Ortho-Substituted P1'S as Factor Xa Inhibitors
Application:
09/833,302 →
Substituted Lactams as Inhibitors of a Beta Protein Production
Application:
09/832,455 →
Fused heterocyclic inhibitors of factor Xa
Application:
60/282,438 →
Integrin Antagonists
Application:
09/828,751 →
Macrocyclic Chelants for Metallopharmaceuticals
Application:
09/826,549 →
Ternary Ligand Complexes Useful as Radiopharmaceuticals
Application:
09/826,449 →
Specific Salt Forms of Triphenylethylene Derivatives as Selective Estrogen Receptor Modulators
Application:
09/824,996 →
Halogenated Triphenylethylene Derivatives as Selective Estrogen Receptor Modulators
Application:
09/824,868 →
Stabilization and terminal sterilization of phospholipid formulations
Application:
60/281,057 →
Cyclic Malonamides as Inhibitors of a Beta Protein Production
Application:
09/825,211 →
Substituted Cycloalkyls as Inhibitors of a Beta Protein Production
Application:
09/824,945 →
Succinoylamino heterocycles as inhibitors of a beta protein production
Application:
09/823,820 →
Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as HIV reverse transcriptase inhibitors
Application:
60/279,217 →
Cyanamide, Alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)- quinazolinones as HIV reverse transcriptase inhibitors
Application:
60/279,214 →
Lactams as Inhibitors of a-Beta Protein Production
Application:
09/817,957 →
6-5, 6-6, or 6-7 heterobicyclic as factor Xa inhibitors
Application:
60/278,173 →
5-6 or 5-7 heterobicycles as factor Xa inhibitors
Application:
60/278,165 →
Cyclic Beta-Amino Acid Derivatives as Inhibitors of Matrix Metalloproteases and Tnf-Alpha
Application:
09/811,233 →
Beta-Amino-Acid Derivatives as Inhibitors of Matrix Metalloproteases and Tnf-Alpha
Application:
09/811,116 →
Peptidase-Cleavable, Targeted Antineoplastic Drugs and Their Therapeutic Use
Application:
09/808,832 →
Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
Application:
60/275,898 →